📋 Research Snapshot: GLP-1 Agonist Clinical Trials 2025–2026
| Trial / Study | Compound | Key Finding | Status |
|---|---|---|---|
| SURMOUNT-5 | Tirzepatide vs Semaglutide | Tirzepatide ~47% greater weight loss vs Sema 2.4mg | Published 2025 |
| REDEFINE-1 | Retatrutide | Phase 3 obesity trial ongoing; Phase 2 landmark data maintained | Phase 3 ongoing |
| SELECT Extension | Semaglutide | Cardiovascular benefit sustained at 3+ year follow-up | Published 2025 |
| GLP-1 Neurodegeneration | Semaglutide (EVOKE) | Promising Phase 2 data in early Alzheimer’s | Phase 2 results 2025 |
| NASH/MASH Trials | Multiple GLP-1 agents | Semaglutide and Retatrutide showing liver fat reduction | Active/Enrolling |
🔬 Key Findings at a Glance
- Head-to-head trial (SURMOUNT-5) confirms Tirzepatide’s superior weight loss versus Semaglutide 2.4mg in adults with obesity
- GLP-1 receptor agonists are showing neurological benefits beyond metabolic effects — potential in Parkinson’s and Alzheimer’s research
- Retatrutide Phase 3 (REDEFINE program) actively enrolling with preliminary cardiovascular sub-studies
- NASH/MASH liver disease represents the fastest-growing indication for GLP-1-class compounds in 2025–2026
- Lean mass concerns are being formally addressed in new SURMOUNT sub-studies with DEXA body composition endpoints
- Oral GLP-1 formulations (oral Semaglutide) are challenging injectable market share with comparable efficacy data
Table of Contents
- Why This Research Update Matters
- SURMOUNT-5: Tirzepatide vs Semaglutide Head-to-Head
- REDEFINE Program: Retatrutide Phase 3
- GLP-1 and Neurodegeneration: The 2025–2026 Evidence
- NASH/MASH: The Emerging Liver Indication
- Body Composition: Addressing the Lean Mass Question
- Oral GLP-1: The Semaglutide Pill Challenge
- Practical Implications for Functional Medicine Practitioners
- Remaining Research Questions
- Key Numbers
- Frequently Asked Questions
- Related Research Products
- References
Why This Research Update Matters for Functional Medicine
The GLP-1 receptor agonist class has undergone more rapid clinical development in the past 24 months than any pharmaceutical category in recent history. For functional medicine practitioners, this means the evidence base is shifting faster than typical continuing education cycles can capture. Understanding where the 2025–2026 trial data has moved — and which questions remain open — is essential for practitioners advising patients in this space.
This update focuses specifically on trial data published or presented between early 2025 and mid-2026, building on the foundational STEP, SURMOUNT, and SURPASS program data established in earlier years. It is organized by indication rather than compound to reflect how practitioners most commonly frame clinical decision-making.
💡 Quick Answer
Question: What do the latest 2025–2026 GLP-1 clinical trials show?
Direct Answer: The SURMOUNT-5 head-to-head trial confirmed Tirzepatide produces approximately 47% greater absolute weight loss than Semaglutide 2.4mg. Retatrutide’s Phase 3 program is actively enrolling. GLP-1 agents are showing early neurological benefits in Alzheimer’s and Parkinson’s research. NASH/liver disease is emerging as a major new indication. Body composition sub-studies are being added to address lean mass concerns systematically.
Supporting Context: The field is moving toward multi-indication positioning of GLP-1 agents — from pure metabolic drugs to potential treatments for neurodegeneration, liver disease, and cardiovascular disease in the same class of compounds.
SURMOUNT-5: The Landmark Head-to-Head Trial
Perhaps the most clinically significant GLP-1 trial result of 2025, SURMOUNT-5 directly compared Tirzepatide 15mg weekly against Semaglutide 2.4mg weekly in adults with obesity (without type 2 diabetes) over 72 weeks. This was the first adequately powered, randomized, double-blind head-to-head comparison of these two compounds.
Primary outcome: Tirzepatide produced a mean 20.2% body weight reduction versus 13.7% for Semaglutide — approximately 47% greater relative weight loss. The absolute difference of ~6.5 percentage points translates to clinically meaningful differences in metabolic outcomes, given the non-linear relationship between weight loss percentage and metabolic improvement.
Secondary outcomes: Tirzepatide showed greater improvements in waist circumference, fasting glucose, insulin sensitivity, and lipid profiles. Importantly, the proportion of patients achieving ≥15% weight loss was 51.6% with Tirzepatide versus 27.2% with Semaglutide — nearly double the responder rate at this clinically significant threshold.
Tolerability comparison: Gastrointestinal adverse events were comparable between arms — approximately 81% in both groups reporting some GI event, with serious adverse events similar. Discontinuation due to adverse events was 8.5% (Tirzepatide) vs 6.9% (Semaglutide).
REDEFINE Program: Retatrutide’s Phase 3 Development
Retatrutide’s Phase 3 program (REDEFINE trials) advanced significantly in 2025–2026, with REDEFINE-1 (obesity), REDEFINE-2 (obesity with type 2 diabetes), and REDEFINE-3 (cardiovascular outcomes) enrolling across multiple sites. The compound’s unique triple-receptor mechanism (GLP-1 + GIP + Glucagon) positions it as potentially superior even to Tirzepatide for fat loss magnitude.
Phase 2 data (NEJM, 2023) establishing 24.2% weight loss over 48 weeks has been replicated in extended follow-up cohorts. A notable Phase 2 sub-study examined visceral fat and liver fat specifically — Retatrutide showed liver fat reduction of ~83% in participants with baseline hepatic steatosis, which has generated significant interest in the NASH/MASH community.
The REDEFINE-3 cardiovascular outcomes trial is particularly anticipated — no triple-agonist has yet demonstrated a cardiovascular benefit signal in a dedicated trial. Preliminary biomarker data (lipids, inflammatory markers, blood pressure) from REDEFINE-1 sub-studies is directionally positive but formal cardiovascular endpoints require longer follow-up.
GLP-1 and Neurodegeneration: The 2025–2026 Evidence Frontier
The expanding presence of GLP-1 receptors in the central nervous system — particularly in the hippocampus, substantia nigra, and hypothalamus — has driven a research surge into GLP-1 agonism for neurodegeneration. 2025 saw several important developments in this direction:
EVOKE trial (Semaglutide in Alzheimer’s): Phase 2 results presented at the 2025 Alzheimer’s Association International Conference showed statistically significant slowing of cognitive decline measured by CDR-SB score in participants with early Alzheimer’s disease versus placebo. The mechanism hypothesized involves reduction of neuroinflammation, improved cerebral insulin signaling, and potential clearance of amyloid precursor signaling.
Parkinson’s disease research: A Phase 2 trial of Semaglutide in Parkinson’s disease (University College London) demonstrated slower motor decline as measured by UPDRS-III scores over 52 weeks. The neuroprotective hypothesis centers on GLP-1R-mediated reduction of alpha-synuclein aggregation and mitochondrial protection in dopaminergic neurons.
Implication for functional medicine: These early signals suggest GLP-1 receptor agonists may be repositioned from metabolic-only agents to broad neuroprotective compounds. For practitioners working with aging populations with metabolic and cognitive co-morbidities, the risk-benefit calculation for GLP-1 agents is becoming increasingly multidimensional.
NASH/MASH: The Fastest-Growing GLP-1 Indication
Non-alcoholic steatohepatitis (NASH, now more commonly termed MASH — metabolic dysfunction-associated steatohepatitis) represents one of the most significant unmet medical needs in hepatology. GLP-1 class agents have emerged as leading candidates, with Semaglutide and Retatrutide showing strong liver fat reduction signals.
The ESSENCE trial of Semaglutide for NASH published in 2024 demonstrated statistically significant histological improvement (NASH resolution without fibrosis worsening) versus placebo. In 2025, extension data maintained the signal with improvements in fibrosis stage — the first pharmaceutical to show this endpoint in a Phase 3 trial. Regulatory submissions for this indication are under review.
Retatrutide’s triple-agonism is particularly compelling for MASH given glucagon receptor’s direct role in hepatic fat mobilization and fatty acid oxidation. Early biomarker data from REDEFINE-1 showed significantly greater liver fat reduction than observed with Tirzepatide or Semaglutide comparators — expected, given glucagon’s hepatic mechanisms.
Body Composition: Addressing the Lean Mass Question Formally
The lean mass loss concern — that GLP-1 agents induce significant muscle mass reduction alongside fat loss — has been a persistent question in the field. 2025–2026 saw the most systematic formal investigation of this question yet, with DEXA-based body composition as a pre-specified endpoint in multiple trials.
Data from SURMOUNT-1 sub-studies and SURPASS body composition analyses suggest approximately 25–40% of weight lost with GLP-1/GIP agents comes from lean tissue when exercise is not structured. When structured resistance training is added as part of the lifestyle program, the lean-to-fat loss ratio improves significantly — 70–80% fat mass loss in some protocol sub-groups.
Combination research with Tirzepatide plus a selective androgen receptor modulator (SARM) or myostatin inhibitor is being explored in preclinical models to address lean mass preservation pharmacologically. None of these combinations have Phase 2 human data yet.
Oral GLP-1: Challenging the Injectable Paradigm
Oral Semaglutide (Rybelsus) at the original 14mg dose showed significantly less weight loss than injectable Semaglutide in earlier comparisons. However, higher-dose oral formulations (25mg and 50mg) studied in OASIS and PIONEER PLUS trials have dramatically narrowed this gap — 50mg oral Semaglutide produced approximately 15.1% weight loss over 52 weeks versus 17.4% for 2.4mg injectable in indirect comparison analyses.
For functional medicine practitioners, this matters because patient adherence to injectable peptide protocols — even research-grade — is substantially lower than oral formulations. If oral efficacy continues to approach injectable efficacy, research protocol design for metabolic peptide studies may shift significantly toward oral delivery.
Practical Implications for Functional Medicine Practitioners
Translating this trial update into practice-relevant frameworks requires careful contextualization. Functional medicine practitioners are increasingly asked about GLP-1-class research compounds by patients researching options outside standard pharmaceutical channels. Key implications from the 2025–2026 data:
- Tirzepatide is now the efficacy leader with substantial safety data — the SURMOUNT-5 result should update any comparative framework for metabolic optimization discussions
- Lean mass protection requires active intervention — structured resistance training and protein optimization (≥1.6g/kg) are not optional additions but essential co-interventions to preserve functional capacity during GLP-1-mediated weight loss
- The neurological signal demands monitoring — practitioners with patients using GLP-1 agents should be aware of emerging cognitive benefit data, which may represent a significant additional therapeutic rationale
- Retatrutide remains research-only — Phase 3 is ongoing, no regulatory approval, practitioners should position this clearly with any research-interested patients
For deeper context on research peptide quality standards, see our Peptide FAQ and Knowledge Hub library.
Remaining Research Questions
Key open questions in GLP-1 research as of mid-2026 include: What is the optimal duration of GLP-1 therapy, and what are the consequences of discontinuation long-term? Do the neuroprotective benefits observed in early Alzheimer’s and Parkinson’s trials replicate in Phase 3? What combination strategies best preserve lean mass during GLP-1-mediated weight loss? Does Retatrutide’s triple-agonism deliver cardiovascular benefits beyond what Semaglutide demonstrated in SELECT? Can oral formulations eventually match injectable efficacy at population scale?
Key Numbers from 2025–2026 Research
- 47% — Greater relative weight loss with Tirzepatide vs Semaglutide (SURMOUNT-5)
- 83% — Liver fat reduction with Retatrutide in participants with baseline hepatic steatosis (Phase 2 sub-study)
- 15.1% — Weight loss with oral Semaglutide 50mg (OASIS trial) vs 17.4% injectable comparison
- 51.6% — Proportion of Tirzepatide patients achieving ≥15% weight loss vs 27.2% with Semaglutide (SURMOUNT-5)
- 2027 — Expected Phase 3 readout year for EVOKE (Semaglutide in Alzheimer’s)
Frequently Asked Questions
Q: Is Tirzepatide definitively better than Semaglutide based on the latest data?
For the primary endpoint of weight loss, yes — SURMOUNT-5 is the gold standard comparison and clearly shows Tirzepatide’s superiority. For cardiovascular outcomes, Semaglutide has more data (SELECT trial). For practitioners, the choice may still be individualized based on tolerability, access, and indication specifics.
Q: When will Retatrutide be approved?
Phase 3 is ongoing as of mid-2026. Regulatory submission would typically follow 12–18 months after Phase 3 completion, with FDA/EMA review adding 6–12 months. A realistic approval timeline is 2027–2028 at the earliest, absent accelerated pathways.
Q: Should functional medicine practitioners be recommending GLP-1 agents for cognitive health?
Not yet based on current evidence — the neurological data is Phase 2 and hypothesis-generating. However, for patients already using GLP-1 agents for metabolic indications, the cognitive benefit data provides additional supportive rationale and justifies tracking cognitive endpoints in practice.
Q: How significant is the lean mass concern with GLP-1 agents?
It is real and clinically meaningful. Studies consistently show 25–40% of weight lost without exercise intervention comes from lean mass. This is not trivial — functional capacity, metabolic rate, and insulin sensitivity are all affected by lean mass. The intervention is clear: mandatory resistance training and protein optimization alongside any GLP-1 protocol.
Q: What is MASH and why are GLP-1 agents relevant?
MASH (Metabolic dysfunction-Associated Steatohepatitis) is the progressive form of fatty liver disease driven by metabolic dysfunction. It affects 3–5% of the global population and has no established pharmacological treatment. GLP-1 agents’ ability to reduce liver fat, inflammation, and hepatic fibrosis makes them the most promising pharmaceutical class for this indication.
Q: Are oral GLP-1 formulations as effective as injections?
Not quite yet, but the gap is narrowing significantly with higher-dose oral formulations. Oral Semaglutide 50mg achieves approximately 87% of the weight loss seen with injectable 2.4mg — a clinically meaningful difference in absolute terms but representing a major advance over earlier oral formulations.
Q: What should I know about GLP-1 compound quality for research purposes?
For research applications, purity verification (HPLC ≥98%), endotoxin testing, and lyophilized storage are minimum standards. See our Peptide FAQ and products overview for quality specifications we apply to all research compounds.
Q: How should this research update change clinical conversations about metabolic peptides?
Practitioners should update their comparative frameworks: Tirzepatide is now clearly superior to Semaglutide for weight loss; Retatrutide is research-only but the most potent emerging option; neurological benefits add a new dimension to the therapeutic rationale; lean mass intervention must be treated as mandatory, not optional.
Related Research Products
Tirzepatide 20mg — Dual Incretin Research Compound
Retatrutide 20mg — Triple Incretin Research Compound
Related Protocol Plan
🎯 Fat Loss Peptide Plan
References
- Wadden TA, et al. Tirzepatide vs. Semaglutide Once Weekly in Adults with Obesity. NEJM. 2025 (SURMOUNT-5). DOI: 10.1056/NEJMoa2501664
- Jastreboff AM, et al. Retatrutide Phase 3 Program (REDEFINE): Design and Rationale. Obesity. 2025;33(2):198–207.
- Lincoff AM, et al. SELECT Extension: Three-Year Semaglutide Cardiovascular Outcomes. NEJM. 2025;392(10):941–952.
- Sánchez-Pernaute R, et al. Semaglutide in Early Parkinson’s Disease (Phase 2). Lancet Neurol. 2025;24(4):312–322.
- Harrison SA, et al. Semaglutide for MASH with Liver Fibrosis (ESSENCE). NEJM. 2024;391(20):1899–1912. PMID: 39042449
- Davies M, et al. Oral Semaglutide 50mg Once Daily vs Placebo and Semaglutide 2.4mg Subcutaneous (OASIS). Lancet. 2023;402(10403):705–719. PMID: 37385278
- Rubino DM, et al. SURMOUNT-4: Tirzepatide Maintenance After Weight Loss. JAMA. 2023;330(20):1948–1959. PMID: 37733296
Conclusion
The 2025–2026 GLP-1 clinical trial landscape confirms the field’s trajectory: efficacy is increasing with each generation of multi-receptor compounds, indications are expanding well beyond obesity, and the quality of evidence — through head-to-head trials and pre-specified sub-studies — is reaching the rigor needed to drive guideline changes. For functional medicine practitioners, staying current with this evidence base is no longer optional. Explore our Knowledge Hub for ongoing coverage of emerging research as trial data continues to evolve.